Future studies employing mast cell-deficient animal models or mast cell depletion strategies (such as knockout mice or targeted pharmacological depletion) will be crucial to definitively establish the extent to which mast cells drive IL-1β production and impair healing in diabetes. This evidence concerns the gene IL1B and diabetes mellitus.